{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T21:06:03Z","timestamp":1769807163171,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12325-025-03422-1","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:26:51Z","timestamp":1764311211000},"page":"377-389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct06475729","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7184-8776","authenticated-orcid":false,"given":"Yuki","family":"Otani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0549-5455","authenticated-orcid":false,"given":"Christopher D.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-6851","authenticated-orcid":false,"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-4046","authenticated-orcid":false,"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-4580","authenticated-orcid":false,"given":"Shomron","family":"Ben Horin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8835-6093","authenticated-orcid":false,"given":"Abhishek","family":"Upadhya K","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7494-8334","authenticated-orcid":false,"given":"Paola","family":"Pellanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"3422_CR1","unstructured":"US Food and Drug Administration: OMVOH (mirikizumab-mrkz) injection, for intravenous or subcutaneous use [Highlights of prescribing information]; 2023. Accessed Sept 2024."},{"key":"3422_CR2","unstructured":"European Medicines Agency: OMVOH (mirikizumab) [Summary of Product Characteristics]; 2023. Accessed Sept 2024."},{"issue":"26","key":"3422_CR3","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444\u201355.","journal-title":"N Engl J Med"},{"issue":"12","key":"3422_CR4","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/ibd\/izae024","volume":"30","author":"BE Sands","year":"2024","unstructured":"Sands BE, D\u2019Haens G, Clemow DB, et al. Two-year efficacy and safety of mirikizumab following 104\u00a0weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflamm Bowel Dis. 2024;30(12):2245\u201358.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"3422_CR5","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ibd\/izae253","volume":"31","author":"BE Sands","year":"2024","unstructured":"Sands BE, D\u2019Haens G, Clemow DB, et al. Three-year efficacy and safety of mirikizumab following 152\u00a0weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflamm Bowel Dis. 2024;31(7):1876\u201390.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"3422_CR6","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"I Usach","year":"2019","unstructured":"Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986\u201396.","journal-title":"Adv Ther"},{"issue":"1","key":"3422_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.gastrohep.2019.06.008","volume":"43","author":"C Gely","year":"2020","unstructured":"Gely C, Mar\u00edn L, Gordillo J, et al. Impact of pain associated with the subcutaneous administration of adalimumab. Gastroenterol Hepatol. 2020;43(1):9\u201313.","journal-title":"Gastroenterol Hepatol"},{"key":"3422_CR8","doi-asserted-by":"publisher","first-page":"115301","DOI":"10.1016\/j.addr.2024.115301","volume":"209","author":"N Mathias","year":"2024","unstructured":"Mathias N, Huille S, Picci M, et al. Towards more tolerable subcutaneous administration: review of contributing factors for improving combination product design. Adv Drug Deliv Rev. 2024;209:115301.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"3422_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cpt.3150","volume":"115","author":"JD Davis","year":"2024","unstructured":"Davis JD, Bravo Padros M, Conrado DJ, et al. Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development. Clin Pharmacol Ther. 2024;115(3):422\u201339.","journal-title":"Clin Pharmacol Ther"},{"key":"3422_CR10","doi-asserted-by":"publisher","unstructured":"Lee SD, Ehrlich AC, Pellanda P, et al. Long-term safety of mirikizumab in patients with moderately to severely active ulcerative colitis: an integrated 2-year safety analysis. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ajg.0000000000003407.","DOI":"10.14309\/ajg.0000000000003407"},{"key":"3422_CR11","doi-asserted-by":"publisher","first-page":"102850","DOI":"10.1016\/j.eclinm.2024.102850","volume":"77","author":"VR Feig","year":"2024","unstructured":"Feig VR, Zhang S, Patel A, et al. Designing for medication adherence in inflammatory bowel disease: multi-disciplinary approaches for self-administrable biotherapeutics. EClinicalMedicine. 2024;77:102850.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"3422_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","volume":"7","author":"A St Clair-Jones","year":"2020","unstructured":"St Clair-Jones A, Prignano F, Goncalves J, Paul M, Sewerin P. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7(4):741\u201357.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"3422_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11095-021-03047-3","volume":"38","author":"GH Shi","year":"2021","unstructured":"Shi GH, Pisupati K, Parker JG, et al. Subcutaneous injection site pain of formulation matrices. Pharm Res. 2021;38(5):779\u201393.","journal-title":"Pharm Res"},{"issue":"10","key":"3422_CR14","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","volume":"62","author":"L Chua","year":"2023","unstructured":"Chua L, Friedrich S, Zhang XC. Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase\u00a0III LUCENT studies. Clin Pharmacokinet. 2023;62(10):1479\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3422_CR15","doi-asserted-by":"publisher","first-page":"e70320","DOI":"10.1111\/cts.70320","volume":"18","author":"L Chua","year":"2025","unstructured":"Chua L, Otani Y, Lin Z, Friedrich S, Durand F, Zhang XC. Mirikizumab pharmacokinetics and exposure-response in patients with moderately-to-severely active Crohn\u2019s disease: results from two randomized studies. Clin Transl Sci. 2025;18(8):e70320.","journal-title":"Clin Transl Sci"},{"issue":"8","key":"3422_CR16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1080\/03007995.2020.1783219","volume":"36","author":"Z Dou","year":"2020","unstructured":"Dou Z, Eshraghi J, Guo T, et al. Performance characterization of spring actuated autoinjector devices for Emgality and Aimovig. Curr Med Res Opin. 2020;36(8):1343\u201354.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"3422_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/17425247.2025.2477656","volume":"22","author":"R Derakhshandeh","year":"2025","unstructured":"Derakhshandeh R, Eshraghi J, Tavakolian M, et al. Performance characterization of spring-actuated prefilled pen devices for lebrikizumab and dupilumab. Expert Opin Drug Deliv. 2025;22(5):747\u201356.","journal-title":"Expert Opin Drug Deliv"},{"issue":"7","key":"3422_CR18","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1365-2702.2005.01121.x","volume":"14","author":"A Williamson","year":"2005","unstructured":"Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14(7):798\u2013804.","journal-title":"J Clin Nurs"},{"key":"3422_CR19","unstructured":"US Food and Drug Administration: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Guidance for industry; 2021. Accessed Sept 2024."},{"issue":"10470","key":"3422_CR20","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase\u00a03, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404(10470):2423\u201336.","journal-title":"Lancet"},{"issue":"2","key":"3422_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/bcp.14155","volume":"86","author":"G Bruin","year":"2020","unstructured":"Bruin G, Hockey HP, La Stella P, et al. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients. Br J Clin Pharmacol. 2020;86(2):338\u201351.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3422_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clinthera.2024.10.016","volume":"47","author":"A Datta-Mannan","year":"2025","unstructured":"Datta-Mannan A, Moser B, Xu W, et al. Evaluation of pharmacokinetics of lebrikizumab in healthy individuals after subcutaneous administration using a prefilled syringe or autoinjector in a phase\u00a01 randomized study. Clin Ther. 2025;47(1):55\u201361.","journal-title":"Clin Ther"},{"issue":"3","key":"3422_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.clinthera.2021.01.009","volume":"43","author":"HK Lon","year":"2021","unstructured":"Lon HK, Cheng L, Nudurupati S, et al. Pharmacokinetic comparability of risankizumab formulations in prefilled syringe and auto-injector for subcutaneous injection. Clin Ther. 2021;43(3):629\u201336.","journal-title":"Clin Ther"},{"issue":"1","key":"3422_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/cts.13109","volume":"15","author":"WD Woodley","year":"2022","unstructured":"Woodley WD, Morel DR, Sutter DE, Pettis RJ, Bolick NG. Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults. Clin Transl Sci. 2022;15(1):92\u2013104.","journal-title":"Clin Transl Sci"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03422-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03422-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03422-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:32:18Z","timestamp":1769765538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03422-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3422"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03422-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuki Otani, Christopher D. Payne, Abhishek Upadhya K, Kristin Todd, Paola Pellanda, Galen Shi, and Xin Zhang are employees and shareholders of Eli Lilly and Company. Edward V. Loftus, Jr. has consulted for Abivax, AbbVie, Astellas, Avalo, Biocon, Bristol-Myers Squibb, Celltrion, Eli Lilly, Fresenius Kabi, Genentech, Gilead, Iota Biosciences, Iterative Health, Janssen, Merck, Morphic, Ono Pharma, Spyre, Takeda, and TR1X Bio; has received research support from AbbVie, Genentech, Gilead, Janssen, Merck, and Takeda; and is a shareholder of Exact Sciences and Moderna. Geert D\u2019Haens has been an adviser and\/or speaker for Abbvie, Alimentiv, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Galapagos, Glaxo Smith Kline, Immunic, Index Pharmaceuticals, Johnson and Johnson, Merck, Polpharm, Prometheus biosciences, Prometheus Laboratories, Procise Diagnostics, Protagonist, Sanofi, Spyre, Takeda, Tillotts, and Ventyx. Shomron Ben Horin has received advisory board and\/or consulting fees from Abbvie, Takeda, Janssen, Celltrion, Pfizer, GSK, Ferring, Novartis, Roche, Gilead, NeoPharm, Predicta Med, Galmed, Medial Earlysign, and Eli Lilly; has stocks\/options in Galmed, Evinature, PredictaMed, and Alma Therapeutics; and has received research support from Abbvie, Takeda, Janssen, Celltrion, Pfizer, Medtronic, and Galmed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with principles derived from the Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines, and the International Council on Harmonisation guidelines and with applicable laws and regulations. The study protocol and the consent forms used were approved by the Salus Institutional Review Board, which covered the ethical approval from each site related to this study (I6T-MC-AMCB). Participants provided written informed consent before they entered the study. The informed consent forms outlined why the research was being done and what it would involve, and it noted that study data that did not directly identify participants could be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}